Cancer stem cells in hepatocellular carcinoma: Therapeutic implications based on stem cell biology (Q38540375)

3 September 2017

1 reference

title

Cancer stem cells in hepatocellular carcinoma: Therapeutic implications based on stem cell biology (English)

1 reference

3 September 2017

main subject

neoplastic stem cells

1 reference

based on heuristic

inferred from title

hepatocellular carcinoma

1 reference

2

Atsushi Iwama

1 reference

3 September 2017

Tetsuhiro Chiba

1

1 reference

3 September 2017

Osamu Yokosuka

series ordinal

3

1 reference

3 September 2017

publication date

29 June 2015

1 reference

3 September 2017

1 reference

3 September 2017

volume

46

1 reference

3 September 2017

issue

1

1 reference

3 September 2017

page(s)

50-57

1 reference

Cancer stem cell definitions and terminology: the devil is in the details.

3 September 2017

cites work

1 reference

https://api.crossref.org/works/10.1111%2FHEPR.12548

Cancer stem cells in solid tumours: accumulating evidence and unresolved questions

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FHEPR.12548

A distinct "side population" of cells with high drug efflux capacity in human tumor cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FHEPR.12548

Side population purified from hepatocellular carcinoma cells harbors cancer stem cell-like properties

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FHEPR.12548

ALDH1 is a marker of normal and malignant human mammary stem cells and a predictor of poor clinical outcome

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FHEPR.12548

Successful isolation of liver progenitor cells by aldehyde dehydrogenase activity in naïve mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FHEPR.12548

Aldehyde dehydrogenase discriminates the CD133 liver cancer stem cell populations.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FHEPR.12548

Visualization of stem cell features in human hepatocellular carcinoma reveals in vivo significance of tumor-host interaction and clinical course.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FHEPR.12548

Wnt/beta-catenin signaling contributes to activation of normal and tumorigenic liver progenitor cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FHEPR.12548

Identification of local and circulating cancer stem cells in human liver cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FHEPR.12548

EpCAM-positive hepatocellular carcinoma cells are tumor-initiating cells with stem/progenitor cell features

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FHEPR.12548

CD13 is a therapeutic target in human liver cancer stem cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FHEPR.12548

CD24(+) liver tumor-initiating cells drive self-renewal and tumor initiation through STAT3-mediated NANOG regulation

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FHEPR.12548

Blockade of CD47-mediated cathepsin S/protease-activated receptor 2 signaling provides a therapeutic target for hepatocellular carcinoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FHEPR.12548

The clonal evolution of tumor cell populations

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FHEPR.12548

Evolution of the cancer stem cell model

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FHEPR.12548

Intratumor Heterogeneity and Branched Evolution Revealed by Multiregion Sequencing

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FHEPR.12548

Distant metastasis occurs late during the genetic evolution of pancreatic cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FHEPR.12548

Discrete nature of EpCAM+ and CD90+ cancer stem cells in human hepatocellular carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FHEPR.12548

Stem cell origin of cancer and differentiation therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FHEPR.12548

EpCAM and alpha-fetoprotein expression defines novel prognostic subtypes of hepatocellular carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FHEPR.12548

Enhanced self-renewal capability in hepatic stem/progenitor cells drives cancer initiation.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FHEPR.12548

Hepatocellular carcinoma: diagnosis and treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FHEPR.12548

Cancer stem cells in hepatocellular carcinoma: Recent progress and perspective

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FHEPR.12548

Stem cells and cancer; the polycomb connection

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FHEPR.12548

Role of the polycomb group proteins in hematopoietic stem cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FHEPR.12548

Polycomb group proteins: multi-faceted regulators of somatic stem cells and cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FHEPR.12548

The polycomb group gene product Ezh2 regulates proliferation and differentiation of murine hepatic stem/progenitor cells.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FHEPR.12548

3-Deazaneplanocin A is a promising therapeutic agent for the eradication of tumor-initiating hepatocellular carcinoma cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FHEPR.12548

Murine inner cell mass-derived lineages depend on Sall4 function

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FHEPR.12548

Sall4 regulates cell fate decision in fetal hepatic stem/progenitor cells.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FHEPR.12548

Sal-like protein 4 (SALL4), a stem cell biomarker in liver cancers

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FHEPR.12548

Oncofetal gene SALL4 in aggressive hepatocellular carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FHEPR.12548

The transcription factor SALL4 regulates stemness of EpCAM-positive hepatocellular carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FHEPR.12548

SALL4 immunoreactivity predicts prognosis in Western hepatocellular carcinoma patients but is a rare event: a study of 236 cases

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FHEPR.12548

Cancer epigenetics: from mechanism to therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FHEPR.12548

21 January 2018

Epigenetics in cancer

1 reference

https://api.crossref.org/works/10.1111%2FHEPR.12548

Histone lysine methyltransferase SUV39H1 is a potent target for epigenetic therapy of hepatocellular carcinoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FHEPR.12548

Alterations of DNA methylation and histone modifications contribute to gene silencing in hepatocellular carcinomas.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FHEPR.12548

Metabolism unhinged: IDH mutations in cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FHEPR.12548

Mutant IDH inhibits HNF-4α to block hepatocyte differentiation and promote biliary cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FHEPR.12548

Identification of microRNA-181 by genome-wide screening as a critical player in EpCAM-positive hepatic cancer stem cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FHEPR.12548

miR-130b Promotes CD133(+) liver tumor-initiating cell growth and self-renewal via tumor protein 53-induced nuclear protein 1.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FHEPR.12548

Self-renewal as a therapeutic target in human colorectal cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FHEPR.12548

EZH2 is essential for glioblastoma cancer stem cell maintenance

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FHEPR.12548

Selective inhibition of EZH2 and EZH1 enzymatic activity by a small molecule suppresses MLL-rearranged leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FHEPR.12548

EZH2 inhibition as a therapeutic strategy for lymphoma with EZH2-activating mutations

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FHEPR.12548

Epigenetic reprogramming modulates malignant properties of human liver cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FHEPR.12548

Antibodies targeting cancer stem cells: a new paradigm in immunotherapy?

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FHEPR.12548

EpCAM-targeted therapy for human hepatocellular carcinoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FHEPR.12548

CD133/prominin-1 is a potential therapeutic target for antibody-drug conjugates in hepatocellular and gastric cancers

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FHEPR.12548

Differentiation therapy of hepatocellular carcinoma in mice with recombinant adenovirus carrying hepatocyte nuclear factor-4alpha gene.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FHEPR.12548

Oncostatin m renders epithelial cell adhesion molecule-positive liver cancer stem cells sensitive to 5-Fluorouracil by inducing hepatocytic differentiation

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FHEPR.12548

Making a tumour's bed: glioblastoma stem cells and the vascular niche.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FHEPR.12548

BAY 43-9006 exhibits broad spectrum oral antitumor activity and targets the RAF/MEK/ERK pathway and receptor tyrosine kinases involved in tumor progression and angiogenesis

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FHEPR.12548

Glioma-initiating cells: a predominant role in microglia/macrophages tropism to glioma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FHEPR.12548

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FHEPR.12548

Metformin: taking away the candy for cancer?

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FHEPR.12548

Metformin, a diabetes drug, eliminates tumor-initiating hepatocellular carcinoma cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FHEPR.12548

The mTOR pathway in hepatic malignancies

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FHEPR.12548

Activation of the PTEN/mTOR/STAT3 pathway in breast cancer stem-like cells is required for viability and maintenance

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FHEPR.12548

Disulfiram, a clinically used anti-alcoholism drug and copper-binding agent, induces apoptotic cell death in breast cancer cultures and xenografts via inhibition of the proteasome activity

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FHEPR.12548

Targeting malignancies with disulfiram (Antabuse): multidrug resistance, angiogenesis, and proteasome.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FHEPR.12548

Disulfiram modulated ROS-MAPK and NFκB pathways and targeted breast cancer cells with cancer stem cell-like properties

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FHEPR.12548

Disulfiram eradicates tumor-initiating hepatocellular carcinoma cells in ROS-p38 MAPK pathway-dependent and -independent manners

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FHEPR.12548

Cytotoxic effect of disulfiram/copper on human glioblastoma cell lines and ALDH-positive cancer-stem-like cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FHEPR.12548

xCT inhibition depletes CD44v-expressing tumor cells that are resistant to EGFR-targeted therapy in head and neck squamous cell carcinoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FHEPR.12548

21 January 2018

Identifiers

DOI

10.1111/HEPR.12548

1 reference

3 September 2017

1 reference